Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Colorcon
Express Scripts
Medtronic
Baxter

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ECULIZUMAB

See Plans and Pricing

« Back to Dashboard

Biosimilar Clinical Trials for eculizumab

This table shows clinical trials for biosimilars. See the next table for all clinical trials
Trial ID Title Status Sponsor Phase Start Date Summary
NCT04058158 A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria Recruiting Samsung Bioepis Co., Ltd. Phase 3 2019-08-01 This is a randomised Phase III, double-blind, multicentre, cross-over study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB12 and SolirisĀ® in subjects with PNH.
>Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for eculizumab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00098280 Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 2004-12-01 This study will examine the safety and effectiveness of the experimental drug eculizumab in treating patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare disorder of red blood cells that leads to premature destruction of the cells and resulting anemia. Patients may be at high risk of blood clots and may develop bone marrow failure or aplastic anemia, with low white blood cell and platelet counts. Eculizumab is a monoclonal antibody that may help improve the survival of red blood cells. Patients 18 years of age and older with PNH who require blood transfusions for anemia and have received at least four transfusions in the 12 months preceding evaluation for this study may be eligible to enroll. Candidates are screened with a medical history, physical examination, and check of vital signs. Participants have an electrocardiogram (EKG) and blood and urine tests, and are vaccinated against Neisseria meningitides, a common bacteria that can cause a disabling or fatal type of meningitis. They then enter an observation phase of the study, with monthly visits during which they complete a questionnaire; update their health status, transfusion record, and medication use; have their vital signs checked and PNH symptoms evaluated; have blood and urine tests; and receive a transfusion, if necessary. These visits continue for up to 3 months until patients receive a "qualifying" transfusion; that is, a transfusion given as a consequence of a certain hemoglobin level with symptoms or a different level without symptoms. Patients are then randomly assigned to receive either eculizumab or a placebo (salt solution with no active ingredient). Both study medications are given intravenously (through a vein) over 30 minutes once a week for five doses and then once every 2 weeks for another 11 doses. At each treatment visit (study weeks 0-24), patients update their health status, transfusion records, and medication use; have their vital signs checked; and provide a blood sample. At various visits, they also complete a questionnaire, provide a urine sample and have an EKG. At the last treatment visit (week 26 or the final visit for patients who end their participation before visit 18) patients have a complete physical examination in addition to the procedures listed above.
NCT00122304 Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab Completed Alexion Pharmaceuticals Phase 3 2004-12-01 The primary objective is to evaluate the safety of eculizumab in patients with transfusion-dependent hemolytic PNH
NCT00122317 Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed Alexion Pharmaceuticals Phase 3 2005-05-01 The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.
NCT00122330 Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Completed Alexion Pharmaceuticals Phase 3 2004-10-01 The primary objective is to evaluate the safety and efficacy of eculizumab in transfusion dependent patients with hemolytic PNH.
NCT00130000 Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 2005-08-01 This study will evaluate the safety and effectiveness of the experimental drug eculizumab for treating paroxysmal nocturnal hemoglobinuria (PNH), a disorder that can cause premature destruction of red blood cells. PNH may result in anemia requiring blood transfusions. Patients may be at high risk of life-threatening blood clots in their veins and may have urine discoloration, stomach pain, difficulty swallowing, tiredness, and poor quality of life. Men may have problems getting or maintaining an erection. Eculizumab is a monoclonal antibody that may improve the survival of red blood cells in patients with PNH. Patients 18 years of age and older who have been diagnosed with PNH for more than 6 months, who have active disease, and who require blood transfusions may be eligible for this study. Each candidate is screened with a physical examination, electrocardiogram, blood and urine tests, and a questionnaire for information on how PNH affects the patient physically, socially, emotionally, and functionally. Participants receive infusions of eculizumab through a needle in a vein once a week for five doses and then every two weeks for another 24 doses. All patients are vaccinated against Neisseria meningitides, a bacteria that can cause symptoms, possibly including life-threatening meningitis, in susceptible people, including people who take eculizumab. At every treatment visit, patients update their health status, transfusion record, and medication use; review their laboratory results from the preceding visit; have vital signs measured; and provide a blood sample for laboratory tests. At selected visits, they also provide a urine sample, have a repeat electrocardiogram, and complete a questionnaire. At the final treatment visit, participants have a complete physical examination, in addition to the routine procedures.
NCT00438789 The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol Approved for marketing Alexion Pharmaceuticals Phase 3 1969-12-31 The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.
NCT00485576 Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma Completed Alexion Pharmaceuticals Phase 2 2007-09-01 This study is to designed to test the role of complement in the late asthmatic response to allergen challenge in mild asthma, as an indicator of the possible role of complement in the broader asthmatic population.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for eculizumab

Condition Name

Condition Name for eculizumab
Intervention Trials
Atypical Hemolytic Uremic Syndrome 8
Paroxysmal Nocturnal Hemoglobinuria 6
Hemoglobinuria, Paroxysmal 5
Paroxysmal Nocturnal Hemoglobinuria (PNH) 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for eculizumab
Intervention Trials
Hemoglobinuria, Paroxysmal 19
Hemoglobinuria 18
Syndrome 15
Hemolysis 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for eculizumab

Trials by Country

Trials by Country for eculizumab
Location Trials
United States 197
Japan 28
Australia 27
Italy 23
Germany 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for eculizumab
Location Trials
New York 18
Maryland 14
California 13
Ohio 11
North Carolina 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for eculizumab

Clinical Trial Phase

Clinical Trial Phase for eculizumab
Clinical Trial Phase Trials
Phase 4 3
Phase 3 12
Phase 2/Phase 3 3
[disabled in preview] 49
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for eculizumab
Clinical Trial Phase Trials
Completed 20
Recruiting 15
Not yet recruiting 10
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for eculizumab

Sponsor Name

Sponsor Name for eculizumab
Sponsor Trials
Alexion Pharmaceuticals 39
National Heart, Lung, and Blood Institute (NHLBI) 3
Mario Negri Institute for Pharmacological Research 3
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for eculizumab
Sponsor Trials
Industry 53
Other 39
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Moodys
Dow
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.